CN Patent

CN109641901B — 阿维巴坦游离酸

Assigned to Sandoz AG · Expires 2022-12-09 · 3y expired

What this patent protects

本发明涉及阿维巴坦游离酸、制备阿维巴坦游离酸的方法以及通过使阿维巴坦游离酸进一步反应而制备阿维巴坦钠的方法。本发明还涉及含有阿维巴坦游离酸、一种或多种碱性钠盐和一种或多种β‑内酰胺抗生素的药物组合物。本发明的药物组合物可用作药物,特别是用于治疗和/或预防细菌感染。

USPTO Abstract

本发明涉及阿维巴坦游离酸、制备阿维巴坦游离酸的方法以及通过使阿维巴坦游离酸进一步反应而制备阿维巴坦钠的方法。本发明还涉及含有阿维巴坦游离酸、一种或多种碱性钠盐和一种或多种β‑内酰胺抗生素的药物组合物。本发明的药物组合物可用作药物,特别是用于治疗和/或预防细菌感染。

Drugs covered by this patent

Patent Metadata

Patent number
CN109641901B
Jurisdiction
CN
Classification
Expires
2022-12-09
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.